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Editor's Note: On April 28, 1984, a special symposium was held during the 52nd Annual Spring Meeting of the 
Minnesota Academy of Sciences. In an attempt to serve the best interests of both the academic research community 
and the general public, this symposium was conceived as a means of shedding light on the recent publicity and 
controversies surrounding the application of the "high tech" discipline called biotechnology. Recent advances in 
biology, particularly molecular biology, have spawned a "new science" called biotechnology. In reality, biotechnol-
ogy encompasses a collection of long-established sciences, that are now augmented by a greater understanding of 
biochemical and genetic processes at the molecular leveL With the advent of recombinant DNA, a new era in biology 
was ushered in whereby knowledge gained from basic research could now be applied in a practical manner to benefit 
humankind. Indeed, biotechnology has been heralded as the ultimate answer to man's problems, as well as the 
ultimate eviL In reality, biotechnology is neither of these things; it is merely a collection of techniques or tools which 
were developed to further our understanding of ourselves and the world around us. 
In an effort to understand both the technical and human nature of this "new" science, this symposium brought 
together two recognized and respected experts in the field of biotechnology: Lynn W. Enquist, former Director of 
Research and Development at Molecular Genetics, Inc., and V. Elving Anderson, Director of the Dight Institute for 
Genetic Research at the University of Minnesota, Minneapolis. The abridged text of Dr. Enquist's and Dr. Anderson 's 
talks are presented on the following pages. 
The Impact of Biotechnology on 
Human and Animal Health 
Lynn W. Enquist 
Lynn Enquist received his doctorate in microbiology from 
the Medical College of Virginia, Richmond, in 1971. From 
1971 through 1973, he served as a postdoctoral fellow in the 
Department of Cell Biology, Roche Institute of Molecular Biol-
ogy. Dr. Enquist held the positions of staff fellow and then 
scientist with the Laboratory of Molecular Genetics (NICHD) 
of the National Institutes of Health from 1973 to 1977, and 
was associated with the virus tumor biology section within the 
Laboratory of Molecular Virology at the National Cancer 
Institute -NIH from 1977through 1981.1n 1981, he became 
Research Director of Animal Health and Plant Products with 
Molecular Genetics, Inc. He has since taken a position with E.! 
Dupont de Nemours, Research and Development Laboratories 
in Wilmington, Delaware. 
gement of genetic information in prokaryotes and eukaryotic 
viruses. He is especially concerned with mechanisms of DNA 
synthesis and control processes active during replication and 
recombination of bacteriophage Lambda and the expression 
of foreign genes in Escherichia coli. As Research Director with 
Molecular Genetics, Inc., he maintained an active research 
interest in the gene structure and Junction in Herpes viruses. 
Herewith follows an abridged transcript of Dr. Enquist 's 
presentation: 
Biotechnology is a novel, and often startling, technology 
that is beginning to make an impact on humanity. I believe 
very few of us realize the impact it is going to have on our own 
personal lives over the next few years. It 's not that these 
innovations are very complicated. To the contrary, the prob-
lem really is that they are so simple. We are not newcomers to 
technical innovation; we have seen several technological 
revolutions that have changed the way we live. Obvious 
examples are nuclear power and computers. The hectic pace 
of our lives continues, and we now find ourselves in the midst 
of another revolution of even greater magnitude than those Dr. Enquist's research interests are focused on the rearran-
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we have experienced before. However, unlike previous tech 
nological breakthroughs, we are in a position, unique in 
mankind's history, to look ahead and see what is in store for us 
while having a chance to direct the technology. The new 
revolution is biotechnology, the manipulation of genes and 
cells. 
The first point to remember is that biotechnology really is a 
technology: it originally represented only a tool that aided 
research. Like other technologies, biotechnology can be 
exploited for commercial purposes. Biotechnology, by my 
definition, is any technique using living organisms or parts of 
organisms to make or modify products, to improve plants or 
animals, or to develop microorganisms or cells for specifi c 
uses. 
Biotechnology has been with us for a long time. From the 
dawn of recorded history, examples exist where man has 
exploited the living creatures around him. He uses microor-
ganisms to improve food by fermentation and exploits wild 
animals and wild plants for domestication through breeding. 
Such applications are examples of directed genetic engineer-
ing in a natural way. Biotechnology is no stranger to us at that 
level. 
But today's revolution in biotechnology is very different. 
Man now has the abili ty to directly manipulate the hereditary 
material (genes) of cells to create new forms of life. It is now 
possible to take genes from one organism and transfer them 
to an unrelated organism. Such gene transfer may result in 
very interesting organisms, or more likely, may result in 
nothing of value. Nevertheless, the important fact is that we 
now have the ability to directly manipulate cells and genes. 
The exciting and frightening issue for some people is that we 
are learning to utilize biotechnology very quickly. Biotech-
nology is not a single discipline ; rather, it is a fusion of a 
whole series of ideas and techniques from many areas of 
study including biochemistry, molecular biology, genetics, 
and physics. The explosion of knowledge in this field has 
become apparent in the last seven years. 
It was in 1840 that Frederick Miescher discovered nuclein, 
an entity that was subsequently proven to be DNA, although 
he did not know that at the time. It took some hundred years 
( 1940) before Avery proved that DNA was the hereditary or 
genetic material of life. In 1953, Warson and Crick deduced 
the structure of the DNA molecule. In 1963,Jacob and Monad 
established the principles by which bacteria regulate their 
genes. At the same time, the genetic code of DNA was broken; 
man could now "speak the language of genes. " In 1967, 
enzymes which could chemically join DNA molecules (DNA 
ligases) were discovered, and in 1970 it was discovered that 
restriction enzymes (which cut DNA at very specific sites or 
locations in the molecule) actually had some value in labora-
tory research. The year 1973 was critical, for it was in this year 
that it became obvious one could purify DNA from an orga-
nism, cut it at predetermined sites with absolute specificity via 
restriction enzymes and then reconstruct the DNA correctly in 
the test tube. This era of recombinant DNA or gene-splicing 
technology had arrived. You can see that it took over a 
hundred years to arrive at that point; however, from 1973 to 
1983, the pace has been explosive. 
In 1974, the first evidence of artificial gene transfer in 
bacteria was obtained. Simultaneously, public awareness that 
recombinant DNA might be something for concern was felt. 
You have probably seen the magazine articles decrying 
"tinkering with life." Scientists felt this social responsibility 
and responded positive ly. In 1975, researchers, for the first 
time in the history of science, declared a public moratorium 
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,)n resea1·ch (involving recombinant DNA). They established 
nationally enforced research guidelines and promoted the 
discussion and review of relevant recombinant DNA research. 
The National Institutes of Health (NIH) guidelines for 
recombinant DNA research are rather detailed and affect only 
those doing research supported by the U.S. government. For 
example, if you receive an NIH grant, you must agree that you 
will follow the NIH guidelines. Although not required to do 
so, priYate companies which do recombinant DNA research 
abide, in principle, to the rules; no responsible company 
would go against the NIH guidelines. 
In 1975 , another breakthrough occurred, the creation of 
hybridoma cells. These are special antibody-producing cells 
formed by fusing two cell types together. A year later, the first 
mammalian gene was isolated and observed in the electron 
microscope, and its total DNA sequence established. 
The first genetic engineering company was established in 
1976 -- Genentech in San Francisco. In 1980, the Supreme 
Court established that one could patent life forms -that is, if 
one "engineered" a new bacterium in the laboratory, one 
could patent it. The decision catalyzed new actiYity in the 
commercial arena. Genentech stock went public in 1980 at an 
initial price of$35. Within 20 minutes of trading, the price rose 
to $89; the gold rush was on! In 1981 , over 80 new companies 
were established to commercialize recombinant DNA tech-
nology. The fi rst fully automated gene synthesizer was made 
in 1980 enabling one to make DNA by machine. Another 
genetic engineering company made records on Wall Street in 
1981 - Cetus, a California company, raised $125 million in an-
initial public offering, the largest offering ever recorded. In 
1982, the first recombinant DNA vaccine, Colibacillosis, was 
developed in Europe. Insulin was produced in bacteria and 
approved for use in the United States and Europe in 1982. 
After 1983, the list of events becomes overwhelming. The 
purpose of this litany of dates is to show that biotechnology is 
moving at an incredible pace -- so fast that even people in the 
field find it difficult to keep up with adYances. The general 
public, therefore, needs to deal with the concern that they 
may not be able to understand the basic issues. The purpose 
of symposia like this is to stress that even though progress is 
very rapid, the technology is rather constant and what is 
fueling progress is the application of this technology to more 
and more problems. Scientists must counter fear with facts ; 
consequently, I want to establish some principles about 
biotechnology, 
As I have indicated, biotechnology involves the restructur-
ing and edi ting of genetic information. In addition, it involves 
restructuring of information to construct new microorga-
nisms which can then be exploited to advance knowledge as 
well as produce products of commercial value. What exactly 
does restructuring and editing of DNA mean? Figure 1A is an 
artist's conception of the double he lix structure of DNA. The 
molecule looks like a ladder in which the rungs contain the 
elements of the genetic code and the outside supports hold 
the molecule together. The rungs of the ladder are chemicals 
called either purines or pyrimidines. The name ofthe purines 
are adenine and guanine and the names of the pyrimidines 
are cytosine and thymine - A, G, T and C are the abbrevia-
tions. The combination of a purine or a pyrimidine and a 
sugar and a phosphate is called a nucleotide. Using the ladder 
analogy, the outside supports are the phosphates and the 
sugars, and the inside rungs are the bases, A, T, G or C. 
DNA has two strands. An A· from one strand always pairs 
with T from the other; similarly, G always pairs with C. The 
strands are held together by such pairings through weak 
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Figure 1. The structure and expression of genetic information. 
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linkages called hydrogen bonds. The genetic code is formed 
by the linear arrangement of the A, T, C and G nucleotides on 
one strand of the DNA molecule. The code has a very simple 
rule about genetic words: all words have only three letters. So 
there are only 64 words in the genetic dictionary ( 4letters and 
3 letters per word= 4 x 4 x 4 or 64 words). A surprising fact 
about words in the genetic dictionary is that some words have 
the same meaning; the code is redundant. A fundamental fact 
of biology is that the genetic code is universal. There are no 
examples of English, Chinese, Russian, or 'Japanese in the 
language of life. All organisms have the same language based 
on DNA. This explains why one can remove a piece of DNA 
from one organism and place it into another one. 
Although life looks fairly complex from an organismic 
point of view, when examined at the molecular level , life is 
fairly simplistic. Perhaps a simple concept to keep in mind is 
that DNA molecules are something like recording tape. 
Recording tape is linear, and the information is generally 
encoded in a linear fashion. To read it, one must start at one 
end and progress stepwise to the other. Splicing recording 
tape is straightforward. One can remove the sixth word from a 
particular statement, join the tape back together and have 
something that may or may not make sense. The key point is 
that one has now edited the tape. The same process can be 
done with DNA. By keeping in mind the analogy of recording 
tape, you will have a good working model of what a DNA 
molecule acts like when it is inside the cell. 
There are three key operational words that define how 
information stored in DNA is used: replication, transcription, 
and translation (Figure 1). In replication, DNA makes a copy 
of itself by separating the two strands and copying each strand 
(Figure lA). Because the strands are complementary, A always 
pairs with T and G always pairs with C. Conceptually it is 
simple to invoke an enzyme that can bring these nucleotides 
together and line them up opposite another strand to make an 
exact copy of the old strand. If this is done coordinately, two 
copies can be made from one DNA molecule. Doing so copies 
the genetic information. DNA, in principle, can be duplicated 
so one copy would go to one daughter cell and one would go 
to the other in the process of cell division. 
The second key word is transcription: how the genetic 
code gets read. The genetic code kept inside the DNA is not 
where the "action is." The DNA is more or less like a hard disc 
storage system on a computer; what is needed is a copy of the 
information that can be sent out for use by the cell. In cells, 
the strands of DNA open and a slightly different nucleic acid is 
copied from one strand, thus providing a message or copy of 
the code that is transported outside the nucleus and put to 
work. This messenger molecule is called mRNA. 
Translation, the third key word, is the reading of the code 
contained in the mRNA copy. The mRNA, like recording tape, 
must be passed over a reader in a linear fashion in order to 
read the code (Figure lB). Remember that the code is read 
three letters at a time. The reading element in cells is called a 
ribosome. The mRNA binds to the ribosome and then ratchets 
through the molecule, moving three bases at a time. Each 
three-letter word, or "codon," specifies one amino acid; 
amino acids are joined together in linear chains to make 
proteins. The key molecule in reading the code is an "adap-
tor" molecule called transfer RNA (tRNA) . Each codon corres-
ponds to a unique adaptor tRNA molecule that has three bases 
complementary to each specific codon. Each tRNA carries one 
specific amino acid to the riboso me. A$ each codon is read, 
the corresponding amino acid is brought in and joined 
together to make a protein. 
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In summary, in replication DNA is duplicated so that all the 
progeny cells get copies of the genetic code. Transcription is 
where the genetic code is copied into RNA and transferred to 
the place where the code is read. Translation, or the reading 
of the code, is the utilization of the information that results in 
construction of proteins. The essence of life can be summa-
rized by what is known as the central dogma: DNA makes 
copies of itself and also makes RNA; RNA makes protein 
(Figure lC). 
With that as general background, let us consider what are 
the major technologies that enabled biotechnology to assume 
such a visible place, not only in research, but also in com-
merce and society. I have defined six techniques that I believe 
represent some of the most important technologies involving 
the manipulation of genes and cells. 
Scientists have perfected the ability to isolate and produce 
faithful copies of isolated genes in quantity and at will. By 
knowing the genetic code and the common structural fea-
tures of the DNA, general principles have been devised to 
identify and purify DNA fragments containing genes of inter-
est. The DNA sequences that encode the self-replication 
machinery of certain viruses and small chromosomes have 
been isolated and are used to replicate DNA fragments in 
simple microorganisms of virtually any source. One can iso-
late a piece of DNA from organisms as diverse as mice, ele-
phants, or plants; insert those DNA segments into self-
replicating DNA units; put the recombined DNA into bacteria 
or yeast; and make many copies of the particular DNA seg-
ments. This is molecular cloning. 
Second, scientists know how to splice genes. DNA is a 
simple repeating polymer that can be cut at specific places 
and rejoined, as well as synthesized in the laboratory from 
common chemicals. Molecular biologists can now take a gene 
from one DNA molecule and chemically splice it to different 
DNA molecule. This feat is called recombinant DNA techno!· 
ogy because new gene combinations are made. The phrase 
"genetic engineering" was coined to describe the microcon-
struction that occurs during gene splicing. 
The third technique is gene transfer. Genes or DNA frag· 
ments can be moved from test tube to living cell almost at will. 
One such method is called micromanipulation. Many copies 
of a gene are isolated and put into a very small glass pipette. 
Using a microscope to guide the process, one can insert the 
glass needle into the nucleus of a single cell and inject the 
purified DNA directly into the nucleus. The new gene often 
functions and replicates in its new environment. In another 
technique, the DNA can be precipitated directly on cell 
surfaces, and the cells take up the DNA much as they would 
take up other objects they encounter. The DNA then makes its 
way to the nucleus where it can function and be inherited for 
generations. 
The fourth technique is cell culture. It is possible to separ-
ate cells from an organism and grow them in a test tube. 
Growing individual cells in quantity for analysis has had an 
enormous impact on biology. Recently this laboratory tool 
has found its way into industry. It is now possible to grow 
mammalian cells in large-scale fermenters much like bacteria, 
which have been exploited by bioengineers for decades. It 
was commonly perceived that only animal cells and microor-
ganisms could grow in culture. However, over the past few 
years, plant cells have become attractive for laboratory and 
industrial exploitation. In addition, certain plant cells have a 
novel property not available with animal cells. After growing 
in culture, plant cells can be coaxed to give rise to whole 
plants. This enables a plant genetic engineer to manipulate 
plant cells in the laboratory such that he or she can work with 
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acres of potential plants in a few petri dishes. 
The fifth technique is cell fusion . Using electric fields or 
chemicals that melt cell surfaces, scientists can fuse two cell 
types together to create a completely different hybrid cell. 
Often these hybrids are unstable and die out, but occasionally 
certain hybrids are stable and provide new forms of cells for 
study and exploitation. 
The sixth basic biotechnology technique involves embryo 
transfer. Eggs from a variety of animals can be fertilized in the 
test tube and the resulting embryos transferred to a suitable 
mother where they develop normally. Since many of the other 
biotechnology techniques listed above involve work with 
DNA and manipulation of single cells, they can be directly 
applied to these germ line cells as well. For example, a 
fertilized egg with new DNA sequences can be transferred to a 
foster mother; the offspring, which can be recovered, now 
carries the new DNA sequences which were inserted into the 
fertilized egg by microinjection or other methods. In this way 
new gene combinations can be introduced into the whole 
animal rather than into individual cells. Presently embryo 
transfer is of great interest in veterinary medicine because it 
enables one to take eggs from a valuable animal, fertilize 
them in a test tube , and implant them in less valuable carrier 
mothers. The prized animal thus bypasses the stress of 
pregnancy. 
Let us now consider a specific example of the application of 
recombinant DNA technology to problems of interest to 
science, medicine, or commerce: the construction of a bacte-
rium synthesizing a protein to be used as a potential Herpes 
virus vaccine. Herpes simplex virus is a complex biological 
agent. It has a lipid overcoat with viral proteins called glyco-
proteins studding the surface. Inside the overcoat is the virus 
capsid, the proteins that cover the DNA molecule of the virus. 
Inside the capsid is a large single DNA molecule of about 
150,000 base pairs that encode about 100-200 genes. The 
glycoproteins on the surface are of medical importance; if 
your body encounters the virus for the first time, your 
immune system responds to these surface glycoproteins by 
making antibodies to the proteins that are on the surface of 
the virus. These antibodies are capable of protecting you from 
a Herpes virus infection. 
What was done to make a recombinant DNA vaccine was to 
isolate the genes that make those surface proteins. Each sur-
face protein gene was then spliced into the DNA of a bacte-
rium so that the viral protein could be made in large quanti-
ties. We can now make the glycoproteins in bacteria and inject 
them into mice or guinea pigs to protect them from infection 
by virulent Herpes simplex virus. The test of this potential 
vaccine in people will probably be initiated early next year. 
Another example of this capability involves transfer of the 
human growth hormone (HGH) gene into mice. This exam-
ple actually brings out a basic ethical issue. Because most 
people are not so much concerned about what can be done 
with bacteria, but rather what can be done with humans, gene 
transfer between humans and mice is striking. The experi-
ment, done two years ago, involved transfer of the human 
HGH gene into mice resulting in offspring twice the size of 
their normal counterparts. The outcome raises many impor-
tant questions. From the scientific point of view, the questions 
of how all of this works are very exciting. From an ethical 
point of view, one must consider if the experiment could or 
should be done in humans. Of course, one can do it in 
humans, because there is nothing special about the technol-
ogy. However, the issues of whether you would want to and 
what the ramifications would be are serious questions yet to 
be answered. 
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Figure 2. The production of monoclonal antibodies. 
Another example of the power of biotechnology is plant 
tissue culture. This is an example of technology developed at 
Molecular Genetics, Inc. Our scientists take immature 
embryos from corn and transfer them to petri dishes contain-
ing nutrients and a plant growth hormone. At first , the 
embryos begin to grow in an undifferentiated manner; they 
form into lumps of tissue called callus. The tissues grow that 
way almost indefinitely as long as they are transferred to fresh 
media containing the plant growth hormone. Such callus 
cultures can be exposed to different environmental insults, 
like herbicides or temperature extremes, and resistant cell 
lines can be isolated and established. This technology brings 
to the realm of plant sciences the ability to manipulate cells 
with the ease and the facility reserved for microbiologists. 
What is truly phenomenal, however, is that one can take these 
clumps of cells, transfer them to media without growth hor-
mone, and regenerate healthy plants. Often these plants have 
the characteristics of the parent plant, but occasionally they 
pick up new traits. If the cells were selected to be resistant to 
an herbicide, for example, the plants regenerated from such 
cells are typically herbicide resistant . Thus, one can manipu-
late plant cells in culture and create novel plants. 
The final exampl e of this new technology is cell fusion , a 
technique now being exploited to create products for both 
human and veterinary marketplaces. In the mid 1970's, a cell 
fusi on technique was developed that gave antibody-
producing cells a kind of immortality (Figure 2). Basically, 
antibody-producing cells are fused with certain long-lived 
cells called myelo ma cells. The antibody cell (which doesn 't 
live very long, but makes the antibody you want) is fused to 
the myeloma cells (which makes nothing that you are inter-
ested in , but lives forever) creating a new kind of cell called a 
hybridoma. Each hybridoma cell must be isolated, cultured 
into colonies, and tested to see if it is making the desired 
antibody. 
Molecular Genetics, Inc. has used this cell fusion technique 
to make our first product, Geneco)TM99, a monoclonal anti-
body. We wanted to make a pure antibody preparation that 
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inactivated a bacterium that causes severe diarrhea in new-
born calves. We did this by first injecting the surface proteins 
ofthis bacterium into mice from which hybridoma cells were 
formed. The right hybridoma cell producing therapeutic 
antibody for this disease of newborn calves was found. The 
antibodies were tested and shown to protect animals against 
disease. We have scaled up this laboratory finding to com-
mercial size and have, to our knowledge, the world's first 
factory manufacturing kilogram quantities of antibody using 
monoclonal technology. 
The striking fact is that this technology was pioneered in 
the late 1960's and was first used only in the laboratory. Only 
recently have we realized that it had any commercial value. In 
two years' time, our scientists identified a problem, designed 
a product, built a factory and have product in a box. The point 
is that biotechnology is really not something of the 21st 
century, but something that is here and now. New products 
and ideas will be coming out at an increasi ng pace, not only 
for agriculture but also for human health care. 
I will end with a summary of some current advances in 
biotechnology. First and most obvious are new products. I've 
discussed some examples of gene products made by 
microorganisms; others include Interferon , tissue plasmino-
gen activator, protein kinases that dissolve blood clots, and 
reagents that are going to be useful in diagnosing cancer. 
Another advance is in gene analysis~ medical diagnosis at 
the molecular level. Scientists now use the same systems for 
isolation and gene transfer to study single genes in a popula-
tion and determine if a given gene is normal or mutant. I 
discussed a particular example where the human growth 
hormone gene was transferred to a mouse. Agromegaly, a 
human growth hormone defect, is treated by giving external 
growth hormones. One can now consider correcting this 
defect by gene transfer of a good human growth hormone 
gene. 
Rapid progress is being made in creating new processes for 
production of chemicals and drugs. There are many examples 
of enzymatic activities present in certain organisms that are 
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difficult to grow. One can now conceive of transferring the 
desired genes to more commercially facile organisms. We can 
expect much research and development in this area. 
Advances in plant tissue culture will provide new plant 
varieties. I discussed the example of corn, but for the past five 
or so years there have been examples of potatoes and raspber· 
ries being, propagated by tissue culture to be virus-free, for 
example. 
Biomass conversion is an area where research is active and 
the benefits are great. A lot of waste from sugarcane, algae, 
weeds, etc. is not used. This biomass contains potential fuel 
and food. Scientists are designing new kinds of bacteria and 
processes to obtain methane, heat, and products from plant 
waste materials. 
A major advance is occurring in instrumentation. I gave an 
example of machines that are being used to synthesize DNA. 
This represents only a small fraction of the machines now 
available to biotechnologists. Whole fields of study are being 
set up to use living cells as part of instruments. For example, 
cells are very sensitive to chemical gradients. Bioprobes may 
be constructed to measure chemicals and events within cells 
with increased sensitivity. 
Computer technology is expanding into biotechnology to 
help scientists understand the molecular process in living 
systems. New concepts are being developed which imply 
using biological molecules as the working components of 
computers - so-called "biochips." Monoclonal antibodies 
and proteins produced in bacteria could be used to build or 
recognize different kinds of information, thus forming novel 
storage and transfer devices. DNA, after all , is the ultimate 
computer - it contains an enormous amount of information 
stored in a very small volume. There are many modern-day 
wizards thinking about ways to make computers based on the 
same kind of techniques that DNA uses to process genetic 
information inside the cell. 
One final item essential to technology is imagination. 
Experiments, products, and impossible techniques become 
not only possible but practical. There are so many possibili-
ties that it boggles the mind. I mentioned producing hor-
mones by microbial fermentation. You can literally produce 
thousands of pounds of hormones this way if you have the 
right kind offermenter. These could be animal hormones that 
improve fertility, milk production, or feed conversion. You 
can insert genes for vaccine antigens or hormones into plants 
using plant tissue culture technology so that people could eat 
these plants and pick up vaccines or hormones through their 
breakfast cereal. You can use plant tissue culture to select 
plant variants resistant to insects, fungi, herbicides, industrial 
pollutants, heavy metals, salt, cold, heat, or flooding. It is 
possible to splice genes for antibodies into microbial facto-
ries; instead of making antisera by injecting antigens into 
animals , you can make antisera by growing a little culture of 
bacteria. You can consider animal breeding, not by conven-
tional technology, but instead by gene transfer, cell culture, 
cell fusion, and embryo transplants. 
It 's clear that these six technical innovations I have pres-
ented plus imagination are indeed the seeds of a revolution in 
all biology. We have a chance to come to grips with a novel 
technology as it's being developed. It is an exciting and 
unique position to be in; the opportunities begin in the 
molecular biology laboratories but provide equally challeng-
ing vistas for every aspect of commerce and for society that 
thinks to capitalize on or be worried about this new revolu-
tion in science and our society. 
••••• 
Volume 50, Number 1, 1984/ 85 
PUBLIC POLICY ISSUES 
CONCERNING BIOTECHNOLOGY 
V. Elving Anderson 
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through 1960 and as acting dean from 1954 through 1965. 
Dr. Anderson has been president of several academic socie· 
ties, including the American Scientific Affiliation, Minnesota 
Academy of Science, Academy Conference of AmericanAsso· 
ciation for the Advancement of Science, the Institute for 
Advanced Christian Studies, and the Behavior Genetics Asso-
ciation. Recently, Dr. Anderson has filled the position of Presi-
dent of Sigma Xi, the Scientific Research Society, and now 
serves on the Boards of Bethel College and Seminary, as well as 
the Institute for Advanced Christian Studies. He currently 
holds the position of Professor of Genetics at the University of 
Minnesota, Minneapolis. 
Dr. Anderson's research interests concern genetic factors in 
epilepsy, mental retardation, diabetes, psychotic disorders, 
and other human behavioral problems. Herewith follows an 
abridged transcript of Dr. Anderson's presentation: 
Many people, when they think about biotechnology and 
genetic engineering, have in mind a picture of Frankenstein 
and his monster. The creature was unusually sensitive, but 
was perceived by others as not human. Therefore, he was 
rejected. Frankenstein's monster has become the symbol ,af 
dangers in the misuse of technology. 
There was another individual who was despised and cast 
aside by society. That person, immortalized in the film Ele-
phant Man, suffered from neurofibromatosis, a disfiguring 
genetic disorder. The extent of the defect can be quite 
variable, from scarcely noticeable to quite severe. The prob-
lem is whether we will be so frightened by the image of 
Frankenstein's monster that we will be unable to deal with 
genetic defects like the one experienced by the Elephant 
Man. 
One possible conceptual framework is presented in Table 
1. In the left column are three functions of science, each with 
an associated cluster of ethical problems. When people think 
about biotechnology or genetic engineering, they often do 
not realize that the greatest use of recombinant DNA methods 
at the present time is at the level of understanding. Now, 
understanding itself does bring some problems. If you find 
out that you are a carrier of a harmful gene, it can affect your 
decisions. For example, if you know you possess the gene for 
Huntington disease, you realize that you are fated to have, 
somewhere between the age of fifteen and fifty-five, the onset 
of a progressive and untreatable neurological disorder. 
The second level is prediction, with the associated ethical 
problems of choice. Prenatal diagnosis, for example, some-
times leads to termination of a pregnancy. I should point out, 
however that no more than about two percent of genetic 
prenatal tests lead to termination. In fact, it is estimated that 
more babies are born as the result of having such tests 
available than are terminated by abortion, since families who 
know they carry genetic defects would otherwise choose not 
to have a child. 
The third level was outlined by Dr. Enquist in his discus-
sion of the possibilities for change and the ethical problems 
that are involved. 
One of the temptations in dealing with science and tech-
nology is to treat problems on too narrow a basis. In this 
discussion, however, I am more concerned about unwar-
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ranted expectations. A physician who writes a column for one 
of our genetic journals told of a woman who stated firmly, 
"Doctor, I do not want to have this baby unless it will be 
perfect." There is no way that anyone can make that guaran-
tee. It is unfortunate that growth in our understanding and 
ability to predict sometimes can lead to the unjustifiable 
conclusion that it is possible to avoid all undesirable 
consequences. 
Another temptation is the misuse of power. Both informa-
tion and techniques for control do convey power. Part of our 
concern here is to keep power as much as possible in the 
hands of the individuals who are directly involved. 
To end with these cautions is not enough, however. In 
order to provide some positive statements, I have used the 
familiar trilogy: faith, hope, and love. Recently I attended a 
conference in Boston on genetics and the law. Albert]onsen, 
an ethicist, told of his experiences in talking with famili es 
who were considering fetal surgery. At present, there are two 
conditions in which operations on the fetus are possible 
- hydrocephalus and urinary tract defects. It is his impression 
that informed consent for the procedure comes only after 
faith in the doctors has been established. The mother or the 
father of the unborn child face many uncertainties , but a 
decision not to intervene also has its problems. That is why 
]onsen described the present status of fetal surgery with the 
phrase "adventures in faith ." At some level there has to be 
faith in someone. 
Hope is also needed. If we are not to be paralyzed by fear 
we need a sense that things can be done correctly. Love also is 
appropriate. Science and technology continually alter our 
concept of what it means to be good neighbors. Table 1 forms 
three sets of three; you can reorganize those terms in a 
number of combinations that will be instructive. 






















Now a few examples. The first will be the topic of recombi-
nant DNA markers. Part of my own research is on a disorder 
called cerebellar ataxia. Each child of an affected parent has a 
50 percent chance of developing the condition. No one shows 
the signs before age fifteen, but everyone who is going to get 
it will do so by age thirty-five. The interval between onset and 
death is seldom more than ten years. We have been studying a 
large family located in Minnesota and South Dakota. Earlier 
studies indicate that the gene for this disorder is on chromo-
some 6 near the genes for HlA. (HlA testing helps to deter-
mine whether or not a donor kidney will be accepted by a 
recipient.) A group in Utah has identified some other markers 
on chromosome 6 that are developed by using restriction 
enzymes to cut DNA. We are now getting new blood samples 
for DNA analysis to see if we can define the location of the 
ataxia gene more precisely. Eventually we hope that these 
recombinant DNA methods will be as successful for cerebel-
lar ataxia as they have been already for Huntington disease. 
When people call us about Huntington disease, we have to 
say that the work is still experimental. We do not know that all 
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of the mutations are alike, since some of the cases may result 
from a mutation on another chromosome. Even when that 
question is resolved, the test will not help all families. In order 
for the results to be informative, an affected person must be 
heterozygous for the markers. Each affected individual has 
one normal and one mutant gene, and each chromosome 
must have a different marker. Furthermore, we have to have at 
least two affected individuals in a family to be able to deter-
mine whether the mutant gene is on the chromosome 
marked A or on the one marked B. 
If you were at risk, would you like to know early in life that 
you do carry this gene? Should we offer this information to 
other relatives who do not yet understand the problem? My 
impression is that people generally would prefer to know, but 
it is not simple. There are ethical issues in transmitting such 
information and in understanding the effect on the life of 
individuals. If you know in fact that you carry this gene, the 
first time you drop something you may say, "Oh, no, it is 
starting." Nonetheles, it would be possible for you to avoid 
reproduction and thus know that you are not transmitting the 
gene to offspring. 
A second illustration involves sickle cell anemia. The 
underlying mutation causes a change in the hemoglobin 
molecule. The altered molecules form stiff rods that distort 
the shape of the red blood cell. The liver and the spleen detect 
these aberrant cells and remove them from circulation. So 
there are a number of other problems that result. 
Adult hemoglobin has four parts, two alpha chains and two 
beta. The alpha chains are made throughout development ; 
the other half of the molecule changes from time to time. In 
the embryo it is the epsilon chain; then the gamma chain is 
produced throughout most of fetal life. Toward the end of 
pregnancy that gene is turned off and the beta gene is turned 
on. The sickle cell mutation is in the beta gene and thus is not 
expressed in the fetus. 
It turns out that the genes are arranged along a chromo-
some in the same seq uence as they are expressed during 
development. There is a reading system and at some point 
one gene is turned off and the next gene is turned on. Some 
individuals have a small chromosome segment missing at the 
switch point and thus make fetal hemoglobin throughout life, 
but the condition usually is not serious. 
There has been some discussion about the individuals who 
have sickle cell anemia. These people who have a mutant beta 
gene might be better off if they had good fetal hemoglobin. 
There are some chemicals that can be used to fool the system 
so that the reading frame will go back a step and produce fetal 
hemoglobin. This would be a form of genetic engineering, 
not by introducing something new, but by changing the 
readout of the genes already there. The trouble is that some of 
the chemicals used are potent carcinogens. 
Martin Cline in California was working with mouse models 
and became interested in beta zero thalassemia, another 
hemoglobin disorder. He wanted to test the possibility that he 
could introduce a normal gene into affected humans. He 
requested permission in California, Italy and Israel. There was 
a very long delay in Cal ifornia, and eventually a denial of the 
request. Permission was granted in Italy and Israel. When he 
carried out the procedure, however, he altered the protocol 
slightly at the last minute. After a long discussion he was 
denied access to new federal funding for some time. 
Shortly thereafter an article was published in the New Eng-
land]ournal of Medicine(Table 2). The question was: When 
can we say that we are ready to carry out gene therapy' The 
conclusion was that for treating thalassemia, none of these 
criteria had been met. So within the academic community 
j ournal of the Minnesota Academy of Science 
self-guiding rules of this sort have been developed. 
Table 2. Criteria for gene therapy. 
1. The new gene should be put into the target cells and remain 
in them. 
2. The new gene should be regulated appropriately. 
3. The presence of the new gene should not harm the cell. 
New England Journal of Medicine, Nov. 27, 1980 
The third illustration is the growth hormone gene. There are 
many different mutations that can lead to dwarfism. One 
group involves short-limbed dwarfism, in which the trunk is 
of normal length but the arms and legs are short. The other is 
proportionate dwarfism, which can result from defective 
growth hormone and other causes. What are the issues for this 
second category? Under what circumstances is short stature a 
defect rather than simply being the low end of a normal 
distribution? Would it be appropriate to use growth hormone 
in cases of dwarfism resulting from some other cause? Cur-
rently children who have slow development resulting from a 
deficiency of growth hormone can be treated with growth 
hormone derived from human cadavers, but this material is 
very expensive and in short supply. Genetic engineering will 
produce human growth hormone in larger quantity and pre-
sumably at lower cost. Furthermore, it is expected that safe 
methods will be developed for the transfer of the gene itself, 
thus avoiding the need for repeated injections. 
These options will make treatment available to most of 
those who have a diagnosed growth hormone defect, but 
there may be the temptation to use the methods to "improve" 
those who are otherwise normal. What if a father comes to a 
doctor saying, "This new baby is wonderful, but I would like 
him to be a basketball player." Is that medically appropriate? 
There may well be serious disadvantages that come from 
giving extra growth hormone. Does the doctor have a right to 
refuse the request under those circumstances? As new tech-
niques and new options become available, public expecta-
tions and pressures can play a large role in shaping the future. 
Faced with these and other current questions, many feel 
intuitively the need for restrictions on future developments. 
One of the persons who has been most vocal concerning 
genetic engineering is jeremy Rifkin. Injune 1983 he released 
a resolution with the concluding statement shown in Table 3. 
This would mean a complete embargo on a procedure, with-
out regard to reasons for its use in a specific situation or 
evidence for its safety. In my opinion, "limits" of this type 
restrict discussion and tend to become outdated by later 
research. My own preference is for the second type of state-
ment, which is very cautious but nevertheless states some of 
the criteria in making a decision. 
One of Mr. Rifkin's supporting arguments is that once we 
begin there is no place to stop (Table 4). That is known as the 
Table 3. Two statements about genetic engineering. 
Efforts to engineer specific genetic traits into the germli ne of the 
human species should not be attempted. (J. Rifkin, 1984. Foun-
dation on Economic Trends. Pp. 276-281 in: Levine, Carol (ed.) 
Taking Sides: Clashing Views on Controversial Bio-Ethical 
Issues. Guilford, CT: Dushkin Publishing Group, Inc.) 
The manipulation of genes in human germ or sex cells, if permit-
ted at all, should be subject to special scrutiny, because not only 
the individual, but also his or her descendants, may be affected. 
(National Council of Churches of Christ/USA, 1984. Genetic 
Engineering: Social and Ethical Consequences. New York: The 
Pilgrim Press.) 
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slippery slope argument, but I do not agree. It is true that we 
must be cautious. One thing may lead to another, but it is not 
inevitable. What about the matter of perfection? As a biologist 
I would argue that aiming at perfection is very different from 
trying to alleviate specific identifiable disorders. Furthermore, 
it is most unlikely that we would narrow the diversity. There is 
such a large pool of diversity that intervention would have a 
very small effect. Rifkin also brings in the eugenics argument 
and invokes the thought of Hitler. Here he confuses the 
distinction between a technology itself and the way in which 
decisions are reached. If the new technology were used in an 
authoritarian way by a government, we would all object 
strongly. But that is a judgment on the means of control, not 
on the technology itself. 
Table 4. Some claims about genetic engineering. 
Once we decide to begin the process of human genetic engi-
neering, there is really no logical place to stop. If diabetes, sickle 
cell anemia, and cancer are to be cured by altering the genetic 
make-up of an individual, why not proceed to other "disorders": 
myopia, color blindness, left handedness. Indeed what is to 
preclude a society from deciding that a certain skin color is a 
disorder? 
What is the price we pay for embarking on a course whose final 
goal is the "perfection" of the human species? ... It is very likely 
that we will succeed in engineering our own extinction. Eliminat-
ing so called "bad genes" will lead to a dangerous narrowing of 
the diversity in the gene pool. 
In place of the shrill eugenic cries for racial purity, the new 
commercial eugenics talks in pragmatic terms of medical 
benefits and improvement in the quality of life. The old eugenics 
was steeped in political ideology and motivated by fear and 
hate. The new eugenics is grounded in medical advance and the 
spectre of extending the human life span. 
(J. Rifkin, 1984. Foundation on Economic Trends. Pp. 276-281 
in: Levine, Carol (ed.) Taking Sides: Clashing Views on Contro-
versial Bio-Ethical Issues. Guilford, CT: Dushkin Publishing 
Group, Inc.) 
My suggestions for the kinds of guidelines that we need are 
shown in Table 5. Obviously the guidelines must make a 
difference by dealing with important issues. They must be 
understandable to the general public, but also present the 
scientific data and issues fairly. Otherwise the people 
involved in science and industry will pay no attention. They 
must involve principles that transcend current science and 
technology, and must recognize points of disagreement. If we 
are going to have guidelines, we should attempt to meet these 
criteria. 
Table 5. Criteria for effective guidelines. 
Effective Guidelines 
1) Make a difference 
2) Are understandable to the general public 
3) Present scientific data and issues fairly 
4) Reach beyond current science and technology 
5) Recognize points of disagreement 
What are the issues that should be addressed (Table 6)? 
The need for caution in technical details is obvious. It is 
important next to encourage reasonable expectations. There 
may be a temptation for a corporation in its public relations to 
make statements about a product that are misleading. We 
should really tell the public what a product can and cannot be 
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Table 6. Guidelines for biotechnology. 
1) Use caution 
2) Encourage reasonable expectations 
3) Avoid harm while doing good 
4) Exercise stewardship 
5) Respect human diversity 
6) Protect individual freedoms 
7) Foster community 
now, and answerable to future generations. A person with 
religious convictions would add answerable to God. 
Fifth is respect for human diversity. There is a tendency to 
talk about deformity or defect in a way that stigmatizes indi-
viduals and treats them as less than human. It is important that 
we protect individual freedom as much as possible. 
8) Recognize the wholeness of human nature 
We can foster community by emphasizing the significance 
of the family, but a broader community may be involved in 
many situations. With regard to the wholeness of human 
nature, Ian Barbour at Carleton has said that we must view the 
human both as a biological organism and as responsible self. 
If we treat a disease without concern for the person, we've 
missed something. When we talk about the possibility of 
"improving" humankind, we should explain carefully what 
we mean. What are the essential points of human nature? 
expected to do. A third principle is to avoid harm but do good. 
At the Boston conference one of the speakers argued that it is 
worse to cause harm than to miss the opportunity to do good. 
What do you think? 
Stewardship is a term used in religious circles, but also in 
conservation. It means that decisions are not self-centered but 
are made in the spirit of answerability - answerable to others 
I conclude with a question found toward the end of the 
President's Commission statement entitled Splicing Life: "By 
what standards and toward what objectives should the great 
new powers of genetic understanding be guided?" 
Clearly, the issues surrounding biotechnology are as numerous as they are complex. Our technological achieve-
ments present us with the ultimate question: How can the capabilities of biotechnology be best used to benefit, not 
harm, humanity? It is imperative that our society attempt to keep pace with our technical capabilities so that the power 
of biotechnology will not be abused. This requires aU persons, whether a representative of academia, industry, or the 
lay public, to cooperate in establishing rational and realistic guidelines for the use of biotechnology. If we do not 
establish a level of confidence and trust in the utilization of this technology, our "brave new world" of the future will 
surely be a dark and dismal one. 
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development function. A recent advance 
in this study was provided by Robert K. 
Herman of the University of Mi nnesota. 
whole chromosome at cell division. By 
utilizing small fragments of normal 
chromosomes Dr. Herman has been able 
to "hide" recessive alleles of develop-
mentally important genes in the normal 
chromosomes. As the worms age they 
tend to lose these fragments and the 
recessive alleles are expressed. By watch· 
ing the timing of the loss and the expres-
sion of the recessive trait it has been 
possible to show when in development 
certain genes are active. 
Academy members interested in be-
coming involved with these activities or 
who want more information should con-
tact The Minnesota Alliance for Science, 
105 Experimental Engineering, 208 
Union Street S.E., University of Minne-
sota, Minneapolis, MN 55455. 
•• * •• 
Science News 
The devel opmental processes of 
higher organisms are the subject of much 
current investigation. One of the key 
questions asked by developmental bi -
ologists is how the genes that control 
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Dr. Herman has taken advantage of the 
biology of the free-living nematode 
worm Caenorhabditis elegansto provide 
evidence for the timing of certain genes 
during development. C. elegans has a 
developmental history characterized by a 
fixed set of cell divisions yielding adult 
worms with identical numbers and 
patterns of cells. Recent work has des-
cribed all the cell divisions and provided 
a complete cell lineage of every cell. 
The chromosomes of this worm are 
not structured li ke the chromosomes of 
most other organisms. Instead of the 
usual small centromere, a structure 
necessary for proper division of the 
chromosome, C. elegans has diffuse cen-
tromeres. These structures allow each 
part of a chromosome to act as if it were a 
The first genes examined in this way 
determine a worm's response to chemi-
cal signals in the environment. It now 
seems that the genes controlling these 
traits act very early in development. What 
remains is to discover the exact mecha-
nism of their expression. 
•• * •• 
Journal of the Minnesota Academy of Science 
